CircuLex anti-CML mouse autoantibody ELISA Kit
Product Code:
MBL-CY-8067
MBL-CY-8067
Host Type:
Mouse
Mouse
Regulatory Status:
RUO
RUO
Application:
Enzyme-Linked Immunosorbent Assay (ELISA)
Enzyme-Linked Immunosorbent Assay (ELISA)
Shipping:
4°C
4°C
Storage:
4°C
4°C
No additional charges, what you see is what you pay! *
| Code | Size | Price |
|---|
| MBL-CY-8067 | 96 Assays | £602.00 |
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
- Further Information
- Documents
- References
- Show All
Further Information
Alternative Names:
(carboxymethyl) lysine
Background:
Reducing sugars react with protein amino groups to form a diverse group of protein-bound moieties with fluorescent and cross-linking properties. These compounds, called advanced glycosylation end products (AGEs), have been implicated in the structural and functional alterations of proteins that occur during aging and long-term diabetes.
Although several AGE structures have been reported (1, 2), it was demonstrated that Nε-(carboxymethyl) lysine (CML) is a major antigenic AGE structure. CML concentration is also increased in patients who have diabetes with complications, including nephropathy (3?5), retinopathy (6), and atherosclerosis (7?9). CML is also recognized by receptor for AGE (RAGE), and CML-RAGE interaction activates cell signaling pathways such as NF-B and enhances the expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells (10).
It has been postulated that AGE structures present in vivo could serve as an immunological epitope to raise autoantibodies against AGE structures, particularly CML. Shibayama et al. showed the presence of autoantibodies against AGE structures, particularly those against CML adduct in streptozotocin (STZ)-induced diabetic rats and patients with several diseases (11, 12). The autoantibody against CML adduct was higher in patients with renal failure than in normal subjects or diabetic patients without renal failure (11). These results suggest that autoantibody against CML might play a possible role in the development of diabetic nephropathy or chronic renal failure.
Description:
The CycLex Research Product CircuLex Anti-CML mouse autoantibody ELISA kit is used for the semi-quantitative measurement of IgG class anti-CML/Nε-(carboxymethyl) lysine mouse autoantibody in mouse serum and plasma.
Gene IDs:
Human: 613 Mouse: 110279
Kit Components:
CML-BSA coated Microplate, BSA coated Microplate, Wash Buffer, Dilution Buffer, Anti-CML mouse Antibody Standard, HRP conjugated Detection Antibody, Substrate Reagent, Stop Solution
Measurement Range:
Dilution factors need to be taken into consideration in calculating the antitoCML antibody concentration. Results exceeding antitoCML autoantibody level of 2000 ng/ml, sample should be repeated with dilution buffer.
Sensitivity:
better than 0.162 ng/mL of sample.
Target:
CML
Documents
References
(1) Ikeda K, Higashi T, Sano H, Jinnouchi Y, Yoshida M, Araki T, Ueda S, Horiuchi S: Biochemistry 35: 8075 ?8083,1996
(2) Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW: Biochemistry 34: 10872 ?10878,1995
(3) Makino H, Shikata K, Hironaka K, Kushiro M, Yamasaki Y, Sugimoto H, Ota Z, Araki N, Horiuchi S: Kidney Int 48: 517 ?526,1995
(4) Suzuki D, Yagame M, Jinde K, Naka R, Yano N, Endoh M, Kaneshige H, Nomoto Y, Sakai H: J Diabetes Complications 10: 314 ?319,1996
(5) Imai N, Nishi S, Suzuki Y, Karasawa R, Ueno M, Shimada H, Kawashima S, Nakamaru T, Miyakawa Y, Araki N, Horiuchi S, Gejyo F, Arakawa M: Nephron 76: 153 ?160,1997
(6) Murata T, Nagai R, Ishibashi T, Inomuta H, Ikeda K, Horiuchi S: Diabetologia 40: 764 ?769,1997
(7) Kume S, Takeya M, Mori T, Araki N, Suzuki H, Horiuchi S, Kodama T, Miyauchi Y, Takahashi K: Am J Pathol. 147: 654 ?667,1995
(8) Sakata N, Imanaga Y, Meng J, Tachikawa Y, Takebayashi S, Nagai R, Horiuchi S, Itabe H, Takano T: Atherosclerosis 141: 61 ?75,1998
(9) Sakata N, Imanaga Y, Meng J, Tachikawa Y, Takebayashi S, Nagai R, Horiuchi S: Atherosclerosis 142: 67 ?77,1999
(10) Kislinger T, Fu C, Huber B, Qu W, Taguichi A, Du Yan S, Hofmann M, Yan SF, Pischetsrieder M, Stern D, Schmidt AM: J Biol Chem 274: 31740 ?31749,1999
(11) Shibayama R, Araki N, Nagai R, Horiuchi S.; Autoantibody against N(epsilon)-(carboxymethyl)lysine: an advanced glycation end product of the Maillard reaction.
Diabetes. 1999 Sep;48(9):1842-9.
(12) Vay D, Vidali M, Allochis G, Cusaro C, Rolla R, Mottaran E, Bellomo G, Albano E.; Antibodies against advanced glycation end product Nepsilon-(carboxymethyl)lysine in healthy controls and diabetic patients. Diabetologia. 2000 Nov;43(11):1385-8.